Matches in SemOpenAlex for { <https://semopenalex.org/work/W2992458322> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2992458322 endingPage "567" @default.
- W2992458322 startingPage "562" @default.
- W2992458322 abstract "Objective To explore the efficacy and toxicities of gemcitabine combined with S-1 in treating locally advanced and metastatic pancreatic ductal adenocarcinoma and prognostic factors. Methods We retrospectively analyzed the clinical data of patients with locally advanced and metastatic pancreatic cancer receiving gemcitabine and S-1 as first-line therapy in the Department of Medical Oncology,Peking Union Medical College Hospital from January 2014 to January 2017.Gemcitabine was administered at a dose of 1000 mg/m2 over 30 min-utes on days 1 and 8,and oral S-1 at a dose of 40-60 mg twice daily from days 1 to 14,repeated every 3 weeks.All patients received at least two cycles of chemotherapy. Results A total of 60 patients were included,13(22%) achieved partial remission,37(61%) had stable disease,and 10(17%) experienced progressive disease.The median progression-free survival was 7 months(95% CI=6-10 months) and the median overall survival was 12 months(95% CI=9-20 months).Both univariate and multivariate analyses of prognostic factors showed primary resection was significant in predicting shorter progression-free survival and lung metastasis was significant for shorter overall survival.The most common grade 3-4 toxicities were neutropenia(27%) and leukopenia(18%). Conclusion Gemcitabine combined with S-1 is an effective regimen with manageable toxicities in the treatment of advanced pancreatic cancer and can be used as first-line therapy.目的 探讨吉西他滨联合替吉奥治疗局部晚期和转移性胰腺导管腺癌的疗效和不良反应,以及可能影响患者生存的因素。方法 回顾性分析北京协和医院肿瘤内科2014年1月至2017年1月病理确诊并接受吉西他滨联合替吉奥方案(第1、8天吉西他滨1000 mg/m2静脉滴注30 min;第1~14天口服替吉奥40~60 mg/次,每日2次,每21天为1个周期)一线治疗的胰腺导管腺癌患者的临床资料,所有患者至少接受2周期化疗、有疗效评估和随访资料。结果 60例晚期胰腺癌患者纳入分析,疾病部分缓解13例(22%),稳定37例(61%),进展10例(17%),总体中位无进展生存期7个月(95% CI=6-10),中位总生存期12个月(95% CI=9-20)。单因素分析和多因素分析均显示原发灶切除对无进展生存期、肺转移对总生存期有显著影响。最常见3~4度不良反应为中性粒细胞减少(27%)、白细胞减少(18%)。结论 吉西他滨联合替吉奥方案一线治疗晚期胰腺癌有效率较高,不良反应易于管理。." @default.
- W2992458322 created "2019-12-13" @default.
- W2992458322 creator A5003573307 @default.
- W2992458322 creator A5017785808 @default.
- W2992458322 creator A5028640794 @default.
- W2992458322 creator A5036427905 @default.
- W2992458322 creator A5043888316 @default.
- W2992458322 creator A5058382693 @default.
- W2992458322 creator A5059953557 @default.
- W2992458322 creator A5060070844 @default.
- W2992458322 creator A5087152698 @default.
- W2992458322 date "2017-08-20" @default.
- W2992458322 modified "2023-09-26" @default.
- W2992458322 title "Efficacy of Gemcitabine and S-1 for Patients with Advanced Pancreatic Cancer." @default.
- W2992458322 doi "https://doi.org/10.3881/j.issn.1000-503x.2017.04.016" @default.
- W2992458322 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28877836" @default.
- W2992458322 hasPublicationYear "2017" @default.
- W2992458322 type Work @default.
- W2992458322 sameAs 2992458322 @default.
- W2992458322 citedByCount "0" @default.
- W2992458322 crossrefType "journal-article" @default.
- W2992458322 hasAuthorship W2992458322A5003573307 @default.
- W2992458322 hasAuthorship W2992458322A5017785808 @default.
- W2992458322 hasAuthorship W2992458322A5028640794 @default.
- W2992458322 hasAuthorship W2992458322A5036427905 @default.
- W2992458322 hasAuthorship W2992458322A5043888316 @default.
- W2992458322 hasAuthorship W2992458322A5058382693 @default.
- W2992458322 hasAuthorship W2992458322A5059953557 @default.
- W2992458322 hasAuthorship W2992458322A5060070844 @default.
- W2992458322 hasAuthorship W2992458322A5087152698 @default.
- W2992458322 hasConcept C121608353 @default.
- W2992458322 hasConcept C126322002 @default.
- W2992458322 hasConcept C141071460 @default.
- W2992458322 hasConcept C143998085 @default.
- W2992458322 hasConcept C144301174 @default.
- W2992458322 hasConcept C2776694085 @default.
- W2992458322 hasConcept C2777063308 @default.
- W2992458322 hasConcept C2778822529 @default.
- W2992458322 hasConcept C2780210213 @default.
- W2992458322 hasConcept C2780258809 @default.
- W2992458322 hasConcept C2780873365 @default.
- W2992458322 hasConcept C2781413609 @default.
- W2992458322 hasConcept C38180746 @default.
- W2992458322 hasConcept C71924100 @default.
- W2992458322 hasConcept C90924648 @default.
- W2992458322 hasConceptScore W2992458322C121608353 @default.
- W2992458322 hasConceptScore W2992458322C126322002 @default.
- W2992458322 hasConceptScore W2992458322C141071460 @default.
- W2992458322 hasConceptScore W2992458322C143998085 @default.
- W2992458322 hasConceptScore W2992458322C144301174 @default.
- W2992458322 hasConceptScore W2992458322C2776694085 @default.
- W2992458322 hasConceptScore W2992458322C2777063308 @default.
- W2992458322 hasConceptScore W2992458322C2778822529 @default.
- W2992458322 hasConceptScore W2992458322C2780210213 @default.
- W2992458322 hasConceptScore W2992458322C2780258809 @default.
- W2992458322 hasConceptScore W2992458322C2780873365 @default.
- W2992458322 hasConceptScore W2992458322C2781413609 @default.
- W2992458322 hasConceptScore W2992458322C38180746 @default.
- W2992458322 hasConceptScore W2992458322C71924100 @default.
- W2992458322 hasConceptScore W2992458322C90924648 @default.
- W2992458322 hasIssue "4" @default.
- W2992458322 hasLocation W29924583221 @default.
- W2992458322 hasOpenAccess W2992458322 @default.
- W2992458322 hasPrimaryLocation W29924583221 @default.
- W2992458322 hasRelatedWork W114644245 @default.
- W2992458322 hasRelatedWork W2045806517 @default.
- W2992458322 hasRelatedWork W2167562354 @default.
- W2992458322 hasRelatedWork W2170588003 @default.
- W2992458322 hasRelatedWork W2350964097 @default.
- W2992458322 hasRelatedWork W2376347278 @default.
- W2992458322 hasRelatedWork W2381460883 @default.
- W2992458322 hasRelatedWork W2442673159 @default.
- W2992458322 hasRelatedWork W3032349186 @default.
- W2992458322 hasRelatedWork W3032604137 @default.
- W2992458322 hasVolume "39" @default.
- W2992458322 isParatext "false" @default.
- W2992458322 isRetracted "false" @default.
- W2992458322 magId "2992458322" @default.
- W2992458322 workType "article" @default.